



Saueressig, T., Owen, P., Pedder, H., Arora, N., Simons, M., Kaczorowski, S., Miller, C., Donath, L., & Belavy, D. (2024). Boosting treatment outcomes via the patient-practitioner relationship, treatment-beliefs or therapeutic setting. A systematic review with meta-analysis of contextual effects in chronic musculoskeletal pain. *Journal of Orthopaedic and Sports Physical Therapy*. Advance online publication. <https://doi.org/10.2519/jospt.2024.12259>

Peer reviewed version

License (if available):  
CC BY

Link to published version (if available):  
[10.2519/jospt.2024.12259](https://doi.org/10.2519/jospt.2024.12259)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the accepted author manuscript (AAM) of the article which has been made Open Access under the University of Bristol's Scholarly Works Policy. The final published version (Version of Record) can be found on the publisher's website. The copyright of any third-party content, such as images, remains with the copyright holder.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:  
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

1        **Boosting treatment outcomes via the patient-practitioner**  
2        **relationship, treatment-beliefs or therapeutic setting. A**  
3        **systematic review with meta-analysis of contextual effects in**  
4        **chronic musculoskeletal pain.**

5        **Authors:**

6        Tobias Saueressig (TS), PT, Dipl.-Vw.<sup>1</sup>

7        Dr Patrick J Owen (PO), PhD<sup>2</sup>

8        Hugo Pedder (HP), PhD<sup>3</sup>

9        Nitin Kumar Arora PT (NKA), MPT<sup>4,5</sup>

10       Marieke Simons (MS), Physiotherapy student<sup>4</sup>

11       Svenja Kaczorowski (SK), PT, MSc<sup>4</sup>

12       Dr Clint T Miller, PhD (CM)<sup>2</sup>

13       Prof Lars Donath (LD), PhD<sup>5</sup>

14       Prof Daniel L Belavy (DB), PhD<sup>4</sup>

15       <sup>1</sup> Physio Meets Science GmbH, Johannes Reidel Str. 19, 69181 Leimen; Germany

16       <sup>2</sup> Deakin University, Institute for Physical Activity and Nutrition (IPAN), School of Exercise and  
17       Nutrition Sciences, Geelong VIC 3220, Australia

18       <sup>3</sup> University of Bristol, Population Health Sciences, Bristol Medical School, UK;

19       <sup>4</sup> (Hochschule für Gesundheit [University of Applied Sciences], Department of Applied Health  
20       Sciences, Division of Physiotherapy, Bochum,

21 <sup>5</sup> German Sport University, Department of Intervention Research in Exercise Training, Cologne,  
22 Germany

23 Twitter: @PhysioMeScience, @PatrickOwenPhD, @BelavyProf, @hugopedder @\_clintmiller  
24 @nitintarika

25 Address all correspondence to Tobias Saueressig at: [t.saueressig@gmx.de](mailto:t.saueressig@gmx.de)

26 **Address:** Physio Meets Science GmbH, Johannes Reidel Str. 19, 69181 Leimen; Germany.

27 **Word count:** 4082 (270 Abstract)

28 **Availability of data and material:** Data and code is available in a public, open access repository.  
29 (<https://osf.io/xzv92/>)

30 **Authors' contributions:**

31 Conceptualization: TS, CM,

32 Data curation: TS, NKA, MS

33 Formal Analysis: TS, HP

34 Funding acquisition: not applicable

35 Investigation: TS, MS, NKA

36 Methodology: TS, HP, DB, PO

37 Project administration: TS Resources: TS, DB

38 Software: TS

39 Supervision: DB, CM, PO, HP, LD

40 Validation: TS, HP

41 Visualization: TS

42 Writing – original draft: TS

43 Writing – review & editing: All.

44 Approved final manuscript: All.

45 Acknowledgments: None.

46 Patient involvement statement: There was no patient involvement in this work.

47 **Statement of financial disclosure and conflict of interest:** I affirm that I have no financial

48 affiliation (including research funding) or involvement with any commercial organization that has

49 a direct financial interest in any matter included in this manuscript, except as disclosed and cited

50 in the manuscript. Any other conflict of interest (i.e., personal associations or involvement as a

51 director, officer, or expert witness) is also disclosed and cited in the manuscript.

52

53 **Abstract**

54 **Objective:** To ascertain whether manipulating contextual effects (e.g. interaction with patients, or  
55 beliefs about treatments) boosted the outcomes of non-pharmacological and non-surgical treatments  
56 for chronic primary musculoskeletal pain.

57 **Design:** Systematic review of randomized controlled trials

58 **Data Sources:** We searched for trials in six databases, citation tracking, and clinical trials registers.  
59 We included trials that compared treatments with enhanced contextual effects with the same  
60 treatments without enhancement in adults with chronic primary musculoskeletal pain.

61 **Data synthesis:** The outcomes of interest were pain intensity, physical functioning, global ratings  
62 of improvement, quality of life, depression, anxiety, and sleep. We evaluated risk of bias and  
63 certainty of the evidence using Cochrane Risk of Bias tool 2.0 and the GRADE approach,  
64 respectively.

65 **Results:** Of 17637 records, we included 10 trials with 990 participants and identified 5 ongoing  
66 trials. The treatments were acupuncture, education, exercise training, and physical therapy. The  
67 contextual effects that were improved in the enhanced treatments were patient-practitioner  
68 relationship, patient beliefs and characteristics, therapeutic setting/environment, and treatment  
69 characteristics. Our analysis showed that improving contextual effects in non-pharmacological and  
70 non-surgical treatments may not make much difference on pain intensity (mean difference [MD] :  
71 -1.77, 95%-CI: [-8.71; 5.16], k = 7 trials, N = 719 participants, Scale: 0-100, GRADE: Low)) or  
72 physical functioning (MD: -0.27, 95%-CI: [-1.02; 0.49], 95%-PI: [-2.04; 1.51], k = 6 , N = 567,  
73 Scale: 0-10, GRADE: Low) in the short-term and at later follow-ups. Sensitivity analyses revealed  
74 similar findings.

75 **Conclusion:** Whilst evidence gaps exist, per current evidence it may not be possible to achieve  
76 meaningful benefit for patients with chronic musculoskeletal pain by manipulating the context of  
77 non-pharmacological and non-surgical treatments.

78 **Trial Registration:** This systematic review was prospectively registered in PROSPERO  
79 (registration number: [CRD42023391601](#))

80 **Keywords:** pain, physiotherapy, review, placebo effects.

81

## 82 **Introduction**

83 Musculoskeletal pain, affecting 16% of the global population, caused 121,300 deaths and 138.7  
84 million disability adjusted life years in 2017,<sup>47</sup> impacting workability,<sup>4</sup> quality of life,<sup>23</sup> and mental  
85 and physical well-being.<sup>24</sup> Non-pharmacological treatments for musculoskeletal pain offer  
86 moderate benefits,<sup>3</sup> but improving treatment outcomes is crucial as global burden grows.<sup>47,49</sup>

87 Contextual effects,<sup>9</sup> including environmental, psychological, social, and cultural elements, can alter  
88 the experiences of individuals with musculoskeletal conditions beyond specific treatment.<sup>8,18</sup> These  
89 factors, including patient expectations, beliefs, previous experiences, and therapeutic relationships,  
90 can influence treatment outcomes.<sup>10,55</sup>

91 Manipulating contextual effects to improve treatment outcomes in musculoskeletal pain conditions  
92 could be a cost-effective and a low-resource alternative.<sup>18,50</sup> However, the literature on systematic  
93 assessments of contextual effects' impact on musculoskeletal conditions is limited. Only one recent  
94 systematic review<sup>50</sup> assessed the impact of contextual effects on clinical outcomes in patients with  
95 low back pain. The review was limited because it included differing comparators and used vote-  
96 counting for synthesis, which is not recommended.<sup>29</sup>

97 We focus on non-pharmacological interventions for chronic primary musculoskeletal pain. These  
98 treatments are often the first line of management due to their potential to minimize the risks  
99 associated with pharmacological treatments or surgical interventions.<sup>33</sup> Enhancing contextual  
100 effects could improve treatment effects, patient satisfaction, help allocate resources, and inform  
101 policy and practice. Our objective was to investigate the impact of contextual effects on managing  
102 musculoskeletal pain.

## 103 **Methods**

104 Our review is reported in accordance with the Preferred Reporting Items for Systematic Reviews  
105 and Meta-Analyses guidelines<sup>2,45</sup> and was prospectively registered in PROSPERO  
106 (CRD42023391601). Data and statistical code are available at the Open Science Framework online  
107 repository (<https://osf.io/xzv92/>).

## 108 **Patient involvement**

109 There was no patient or public involvement.

## 110 **Search strategy**

111 The whole search strategy is presented in Supplement 1. The electronic databases of MEDLINE,  
112 EMBASE, CINAHL, Web of Science Core Collection, CENTRAL, and SPORTDiscus were  
113 searched. The search terms were combined using the ‘AND’ operator to capture relevant trials  
114 across all domains. The search strategy was partially based on one systematic review identified in  
115 the literature.<sup>50</sup>

116 The search was limited to trials that were published from inception up to December 15, 2022.  
117 Unpublished and ongoing trials were searched through the WHO International Clinical Trials  
118 Registry Platform ([http:// www.who.int/ictrp/en/](http://www.who.int/ictrp/en/)) and the US National Institutes of Health  
119 ClinicalTrials.gov (<https://clinicaltrials.gov/>). A search for prior systematic reviews was conducted  
120 using the Cochrane Database of Systematic Reviews and GoogleScholar  
121 (<https://scholar.google.de/>) (see Supplement 1). We also performed forward and backward citation  
122 tracking in Web of Science on March, 28, 2023 for the included trials and relevant systematic  
123 reviews.



## 124 **Eligibility criteria**

125 The inclusion criteria followed the Participants, Interventions, Comparators, Outcomes, and Study  
126 design (PICOS) framework.<sup>45</sup>

127 Participants: Adults ( $\geq 18$  years) experiencing primary chronic musculoskeletal pain.<sup>56</sup> Chronic  
128 primary pain, as per the ICD-11, is pain persisting for more than three months in one or more body  
129 regions, accompanied by significant emotional distress or functional disability, and not attributable  
130 to another chronic condition.<sup>46</sup> Chronic pain was defined as pain duration at baseline  $\geq 3$  months.  
131 There were no restrictions based on sex or race.

132 Interventions: An enhanced intervention was defined as any intervention designed to change or  
133 modify one or more known contextual effects of the health encounter/clinical consultation or  
134 experimental condition.<sup>50</sup> Possible contextual effects could be the ones described by previous  
135 authors<sup>18</sup> and entail: 1) patient beliefs and characteristics (e.g., medical history, illness and  
136 treatment beliefs, expectations, or prior experiences); 2) practitioner beliefs and characteristics  
137 (e.g., professional reputation, attire, empathy, professional training and prior experiences, and  
138 beliefs about treatment effectiveness); 3) patient-practitioner relationship (e.g., therapeutic  
139 alliance, trust, verbal or non-verbal communication, reassurance); 4) therapeutic  
140 setting/environment (e.g., setting, layout, décor, interior design); and 5) treatment characteristics  
141 (e.g., continuity of care, labelling, visual cues, sham/dummy treatment, variations in touch or  
142 stimulus conditions).<sup>50</sup> The intervention encompassed any non-pharmacological intervention as  
143 defined in Supplement 2.

144 Comparators: The same intervention without enhancement of contextual effects.

145 Outcomes: The choice of outcome measures were influenced by Dworkin’s core outcome measures  
146 set.<sup>20</sup> The primary outcomes of interest included measures of pain intensity and physical  
147 functioning. Secondary outcomes encompassed global ratings of improvement, health-related  
148 quality of life, depression, anxiety, and sleep impairment. The follow-up time points were  
149 categorized as immediate (<1 day), short-term ( $\geq 1$  day but <3 months), intermediate-term ( $\geq 3$   
150 months but <12 months), and long-term ( $\geq 12$  months). A 10-point between-group difference was  
151 established as a range of equivalence for pain on a 0- to 100- numeric pain rating (NRS) scale.<sup>44</sup>  
152 The range of equivalence for outcomes with standardized mean differences (SMD) was set at a  
153 value of  $SD=0.50$ ,<sup>42</sup> indicating situations where differences between interventions are not clinically  
154 significant.<sup>41</sup>The range of equivalence was transformed to the original scale by multiplying with  
155 the corresponding reference SD.

156 Study design: Randomized trials (individual or cluster or cross-over) conducted in English or  
157 German. The trials compared a contextually “enhanced” intervention with the same intervention  
158 without enhancement. Only full-text articles were considered.

159 The exclusion criteria are listed in Supplement 3.

## 160 **Data extraction**

161 Two independent assessors (NKA, TS) screened and extracted data using custom data extraction  
162 sheets, resolving disagreements through a third reviewer (PO). Extracted information included  
163 publication details, study design, demographics, main results, and follow-up duration. Mean and  
164 standard deviation (SD) were extracted for main results, with missing SD imputed using regression.  
165 Guidelines for handling randomized cross-over and cluster randomized trials were followed.<sup>29</sup>  
166 Multiple groups within a trial were combined when possible, and outcomes on different scales were  
167 standardized and combined using appropriate methods.<sup>12</sup> Data from figures were extracted using

168 GetData Graph Digitizer.<sup>25</sup> Any discrepancies in extracted data were resolved through discussion  
169 among assessors, with adjudication by a third researcher if needed (Supplement 4).

## 170 **Risk of bias assessment and GRADE**

171 The revised Cochrane Collaboration Risk of Bias Tool (RoB 2) was used to assess potential biases  
172 in both individually and cluster randomized trials.<sup>29,52</sup> Each source of bias was classified as having  
173 a low risk, some concerns, or high risk. Current guidelines from the Cochrane Collaboration<sup>21</sup>  
174 provide no definite guidance on how many outcomes and how many follow-up time-points should  
175 be assessed. All included outcomes were self-reported by the included participants. To prioritise  
176 workload, the assessment of the risk of bias was based on the results obtained at the last follow-up  
177 time point of the study. One subjective outcome (pain intensity) was rated.<sup>29,52</sup> Two independent  
178 assessors (NKA, TS) performed the ratings. A third adjudicator (DB) resolved disagreements as  
179 required.

180 The quality of evidence for pairwise comparisons was assessed using the Grading of  
181 Recommendations Assessment, Development and Evaluation (GRADE) approach.<sup>27</sup> The criteria  
182 from Confidence in Network Meta-Analysis (CINeMA) evaluated imprecision, inconsistency, and  
183 publication bias.<sup>41</sup> For a detailed overview of our approach see Supplement 5. We used custom-  
184 made analysis R code to semi-automatically assess the GRADE criteria. Results of this ratings  
185 were double checked by two adjudicators (TS, SK).

## 186 **Statistical analysis**

187 We employed a lumping approach in our meta-analyses to test for the existence of intervention  
188 effects.<sup>19,26</sup> When pre- and post-treatment SD correlation was unavailable, we used  $\rho = 0.59$ , with  
189 sensitivity analysis at  $\rho = 0.40$  and  $0.81$ .<sup>6</sup> Effect sizes were MD for pain scales (converted to a 100-

190 point NRS) and SMD with an internal reference SD<sup>17</sup> for other outcomes, interpreted as small ( $\geq$   
191 0.2 SD), moderate ( $\geq 0.5$  SD), and large ( $\geq 0.8$  SD) following Cohen.<sup>15</sup> SMD for physical function  
192 and quality of life were back converted to original scales (for further details see Supplement 6).  
193 Reverse-scaled trials were adjusted by multiplying means by -1. Random-effects meta-analysis was  
194 conducted with REML estimation, and confidence intervals were calculated using Knapp-Hartung  
195 method. Heterogeneity was assessed with Cochran Q, chi-squared statistic, I<sup>2</sup>, and 95% prediction  
196 intervals when the number of trials was  $\geq 5$  and tau  $> 0$ . Funnel plots and Egger's test assessed  
197 small study effects and publication bias only if  $\geq 10$  trials were available.<sup>53</sup> Meta-regression was  
198 performed only if  $\geq 10$  trials were available.<sup>11</sup> Analyses were conducted in R (version 4.3.1) using  
199 Meta and metafor packages.<sup>5,57</sup> Conclusions were drawn based on the guidelines in the Cochrane  
200 Handbook.<sup>29</sup>

201

## 202 **Subgroup Analysis**

203 If the number of available trials was  $\geq 10$ , we planned subgroup analyses and/or random effects  
204 meta-regression on: pain condition (e.g. low back pain, hip pain, etc.), type of intervention, risk of  
205 bias, usage of intention-to-treat analysis or per protocol analysis.

## 206 **Sensitivity Analysis**

207 Sensitivity analysis was performed via outlier identification and influence analysis if there were  
208 more than 10 trials in the analysis.<sup>58</sup> The impact of the choice of correlational values for calculating  
209 the SD of the change-from-baseline was assessed. We performed meta-analysis with unrestricted  
210 weighted least squares (UWLS) to account for small-study effects and high heterogeneity.<sup>51</sup> We  
211 planned to perform a sensitivity analysis for missing participant data if the percentage of missing

212 data was over 30% for the corresponding meta-analytic outcome but this analysis was not  
213 conducted as the missing data was always less than 30%.<sup>60</sup>

## 214 **Results**

215 We identified 17,637 reports. After removing duplicates and screening titles and abstracts of all  
216 remaining unique reports, 177 full-text reports were assessed for eligibility. We included 10 trials  
217 with 10 study reports (Figure 1).<sup>28</sup> Literature sources and reasons for exclusion of ineligible trials  
218 are in Supplement 7. We identified 5 ongoing trials potentially relevant for this review (Supplement  
219 8).<sup>13,16,38-40</sup>

## 220 **Study characteristics**

221 The characteristics of the 10 included trials are shown in Table 1. Sample size ranged from 12 to  
222 127 participants (mean: n=49.7; total: n=994). Mean (SD) age of participants was 47.8 (11.1) years.  
223 The median (range) intervention duration was 3 (0.14-8) weeks. The duration of complaints was  
224 median (range) 205.15 (16.25-747.5) weeks. The chronic MSK conditions were: knee osteoarthritis  
225 (n=1),<sup>32</sup> knee and-hip osteoarthritis (n=1),<sup>48</sup> lateral epicondylalgia (n=1),<sup>35</sup> plantar heel pain  
226 (n=1),<sup>37</sup> rotator cuff-related shoulder pain (n=1),<sup>1</sup> and low back pain (n=5).<sup>7,22,34,36,59</sup> Interventions  
227 were classified as acupuncture (n=2),<sup>7,32</sup> aids and devices (n=1),<sup>1</sup> education (n=1),<sup>36</sup> electrophysical  
228 agents (n=2),<sup>22,37</sup> exercise training (n=1),<sup>48</sup> manual therapies (n=1),<sup>35</sup> and physical therapy  
229 treatment (n=2).<sup>34,59</sup>

230 Six trials<sup>7,22,32,34,36,48</sup> were funded by governmental organizations, three trials<sup>35,37,59</sup> did not report  
231 their funding source, and one trial<sup>1</sup> reported no funding. Six trials<sup>1,7,35,36,48,59</sup> stated no conflict of  
232 interest, two trials<sup>32,34</sup> declared a conflict of interest, and two trials<sup>22,37</sup> did not report their conflict  
233 of interest. Trials were assigned to the following enhancement categories (Table 2): patient-

234 practitioner relationship (n=4),<sup>22,34,36,59</sup> patient's beliefs and characteristics (n=4),<sup>1,7,32,35</sup> therapeutic  
235 setting/environment (n=1),<sup>48</sup> and treatment characteristics (n=1).<sup>37</sup>

## 236 **Risk of bias**

237 We assessed the outcome pain intensity at the longest follow-up time-point available in the trial.  
238 Two trial outcomes were rated as low RoB overall.<sup>34,48</sup> The other trial outcomes were either rated  
239 with some concerns (k=7)<sup>1,7,22,35-37,59</sup> or a high RoB overall (k = 1)<sup>32</sup> (Supplement 9). One trial was  
240 assessed with the ROB tool 2.0 for cluster RCTs.<sup>34</sup>

## 241 **Data handling and synthesis**

242 All data transformations (i.e. conversion of CI to SD, conversion of medians to means and SD) can  
243 be retraced via our analysis code which is openly available on the Open Science Framework  
244 (<https://osf.io/xzv92/>). One trial reported medians and interquartile range which were transformed  
245 to a mean with a corresponding SD.<sup>35</sup> In one trial, data were extracted from figures.<sup>37</sup> The included  
246 cluster RCT<sup>34</sup> did not need adjustment of the standard error because the trial reported adjusted  
247 results for clustering. No SDs were imputed.

248 All meta-analysis outcomes are reported in Table 2 and figures 2-5. SMD analyses of physical  
249 function and quality of life are shown in Supplement 10. The internal reference SD for  
250 standardization can be found in Supplement 11. All individual trial outcomes can be found in  
251 Supplement 12.

## 252 **Primary Outcomes**

### 253 *Pain Intensity*

254 All trials (k = 10) reported on the outcome pain intensity (Figure 2).<sup>1,7,22,32,34-37,48,59</sup>

255 At immediate follow-up, 2 trials reported on pain intensity.<sup>1,22</sup> A (MD: -7.99, 95%-CI: [-77.46;  
256 61.47], k = 2 , N = 125, GRADE: Very Low) with very uncertain evidence was estimated. Short-  
257 term results for pain intensity were reported in 7 trials.<sup>7,32,35-37,48,59</sup> In our analysis, we observed a  
258 small effect favoring the intervention group (MD: -1.77, 95%-CI: [-8.71; 5.16], 95%-PI: [-19.51;  
259 15.96], k = 7 , N = 719, GRADE: Low) in the short-term. For the intermediate-term, 5 trials  
260 reported on pain intensity.<sup>7,34,36,37</sup> A small effect in favour of the intervention group was estimated  
261 (MD: -0.81, 95%-CI: [-6; 4.38], k = 5 , N = 238, GRADE: High). Long-term results for pain  
262 intensity were reported in 2 trials.<sup>36,37</sup> A small effect (MD: -0.49, 95%-CI: [-6.37; 5.4], k = 2 , N =  
263 616, GRADE: High) was estimated for pain intensity in the long-term. All three estimated  
264 outcomes did not translate into clinically meaningful differences in outcomes.

### 265 *Physical Functioning*

266 Eight trials examined the effect of contextual enhancement on physical function outcomes (Figure  
267 3).<sup>1,32,34-37,48,59</sup> The results are on the patient-specific functional scale which ranges from 0-10.

268 One trial<sup>1</sup> reported immediate-term outcomes and found a moderate effect (MD: 1.2, 95%-CI:  
269 [0.65; 1.75], k = 1 , N = 66, GRADE: High) in favour of the control group. Six trials reported short-  
270 term outcomes and showed a small effect (MD: -0.27, 95%-CI: [-1.02; 0.49], 95%-PI: [-2.04; 1.51],  
271 k = 6 , N = 567, GRADE: Low) which may make no difference.<sup>32,35-37,48,59</sup> Four trials reported  
272 intermediate-term outcomes and revealed a small effect (MD: -0.1, 95%-CI: [-1.08; 0.88], k = 4 ,  
273 N = 238, GRADE: Moderate) in favor of the enhancement group which likely makes no clinically  
274 significant difference in outcomes.<sup>34,36,37</sup> Two trials reported long-term outcomes and found a small  
275 effect (MD: -0.9, 95%-CI: [-8.32; 6.55], k = 2 , N = 464, GRADE: Low) which may make a slight  
276 difference in results.<sup>36,37</sup>

## 277 **Secondary Outcomes**

### 278 *Global Ratings of Improvement*

279 Three trials examined the effect of contextual enhancement on global ratings of improvement  
280 (GROC) outcomes (Figure 4).<sup>34,36,48</sup>

281 For short-term outcomes, 2 trials reported a small effect (SMD: 0.18, 95%-CI: [-2.16; 2.52], k = 2  
282 , N = 148, GRADE: Low) in favour of the control group which may result in little or no difference  
283 in outcomes.<sup>36,48</sup> For intermediate-term outcomes, 2 trials reported a small effect (SMD: -0.13,  
284 95%-CI: [-0.93; 0.67], k = 2 , N = 401, GRADE: Low) in favor of the enhancement group which  
285 may result in little or no difference in outcomes.<sup>34,36</sup> For long-term outcomes, one trial revealed a  
286 small effect (SMD: -0.39, 95%-CI: [-0.77; -0.01], k = 1 , N = 230, GRADE: High) in favor of the  
287 enhancement group.<sup>36</sup>

### 288 *Health-related quality of life*

289 Three trials investigated the impact of contextual enhancement on health-related quality of life  
290 outcomes at different time-points (Figure 5).<sup>32,34,48</sup> The results are on the SF-36 mental component  
291 scale, which ranges from 0-100.

292 For short-term outcomes, 2 trials reported a very uncertain effect (MD: 0.31, 95%-CI: [-37.64;  
293 38.15], k = 2 , N = 253, GRADE: Very Low) in favor of the control group.<sup>32,48</sup>

294 For intermediate-term outcomes, one trial found no effect of contextual enhancement on health-  
295 related quality of life (MD: 1.43, 95%-CI: [-1.94; 4.79], k = 1 , N = 126, GRADE: High) in favor  
296 of the control group.<sup>34</sup>



297 **Other Outcomes**

298 The outcomes “self-reported depression”, “self-reported anxiety”, and “sleep impairment” were  
299 not reported in any of the included trials.

300 **Subgroup Analysis**

301 We performed an a posteriori subgroup analysis for trials that included low back pain patients  
302 (Supplement 13). Subgroup analyses for both outcomes showed no substantial difference in  
303 comparison to the main analyses

304 **Sensitivity Analysis**

305 We did not perform outlier identification and influence analysis due to the low number of trials  
306 included in each analysis. A sensitivity analysis for missing participant data was not performed as  
307 the percentage of missing data was never over 30% for any meta-analyses. The impact of imputed  
308 SD was not assessed as we did not impute any SD and only converted one trial from median to  
309 mean and SD. The results for the UWLS analysis to account for small-study effects and high  
310 heterogeneity can be found in Supplement 14.

311 Sensitivity analysis showed differences for the outcome global rating of change in the short and  
312 intermediate term. The estimates reversed their direction favouring the control group in the short-  
313 term and favouring the intervention group in the intermediate term for the UWLS analyses. The  
314 precision of the estimates was lower for the UWLS analyses compared to the main analyses. The  
315 sensitivity analyses for different correlational values for the imputation of the change from baseline  
316 SD did not show any important differences in results (Supplement 15). We also performed an a  
317 posteriori sensitivity analysis where we changed the time-frame for the immediate follow-up to

318 one week (Supplement 16). No important differences were noted in comparison to our pre-specified  
319 analysis.

### 320 **Certainty of evidence**

321 Main reasons for downgrading the evidence were imprecision and inconsistency. We did not grade  
322 down due to publication bias in accordance with our pre-specified criteria as we found no empirical  
323 evidence for publication bias in the literature and we performed extensive searches to rule out  
324 missing trials in our search. Indirectness was not downgraded.

### 325 **Reporting Biases**

326 We did not assume that reporting bias was present because we performed a comprehensive search,  
327 and identified no empirical evidence for publication bias. Statistical evidence could not be assessed  
328 as there were not enough trials to get reliable test results.

### 329 **Amendments to information provided at registration**

330 The amendments to our protocol are in supplement 18.

### 331 **Discussion**

332 Enhancing contextual effects in non-pharmacological and non-surgical interventions for chronic  
333 primary, musculoskeletal pain did result in little to no differences between the enhancement group  
334 and the control group for pain intensity (very low to high certainty evidence) and physical  
335 functioning (low to high certainty evidence) outcomes across immediate-term, short-term,  
336 intermediate-term, and long-term follow-up time-points. Short-term and intermediate-term global  
337 ratings of improvement showed no substantial differences, while the long-term outcome favored  
338 the enhancement group which showed a small effect favoring the enhancement group (low to high

339 certainty evidence). The impact on health-related quality of life outcomes was uncertain (very low  
340 to high certainty evidence), with no substantial differences in the short-term. In the intermediate-  
341 term there was evidence of no effect for the enhancement of interventions. Findings from meta-  
342 analysis in the subgroup of trials including only patients with low back pain were consistent with  
343 the wider meta-analyses.

344 Some individual trials showed beneficial and relevant effects. These findings highlight the varying  
345 effects of different interventions on pain intensity, physical functioning, and global ratings of  
346 improvement, emphasizing the need for further research in these areas to inform clinical practice  
347 and enhance patient outcomes. A small trial<sup>22</sup> demonstrated a moderate immediate decrease in pain  
348 intensity through enhanced therapeutic interaction, while another<sup>36</sup> found no short-term effect of  
349 therapeutic alliance. Kong et al.<sup>32</sup> showed a significant short-term reduction in pain intensity using  
350 “boosted acupuncture” with expectancy manipulation, whereas Barth et al.<sup>7</sup> did not. For physical  
351 functioning, Kong et al.<sup>32</sup> reported a significant short-term improvement for “boosted  
352 acupuncture”, but with a high risk of bias and small sample size. Morral et al.<sup>37</sup> found no significant  
353 effect in the short term but observed a beneficial effect in the long term for physical function for a  
354 shockwave device with a more sophisticated design. Martínez-Cervera et al.<sup>35</sup> reported a moderate  
355 non-significant effect on physical functioning with a small sample for manual therapy with  
356 enhanced patient expectations. In terms of global ratings of improvement, Miyamoto et al.<sup>36</sup> found  
357 little difference in short-term and intermediate-term outcomes but demonstrated a moderate effect  
358 in the long term for enhancing therapeutic alliance.

### 359 **Results in context of other evidence**

360 Our findings have implications for existing literature and current clinical practices. The lack of  
361 considerable differences in all outcomes suggests that enhancing contextual effects may not have

362 a substantial impact in the treatment of chronic primary musculoskeletal pain. Some trials  
363 suggested that enhancing treatment expectations could improve treatment outcomes. Nevertheless,  
364 our findings do not align with previous research<sup>18,50</sup> that concludes that leveraging contextual  
365 effects could improve patient-reported outcomes.

366 We reached a different conclusion to the most recent systematic review.<sup>50</sup> There are a few  
367 explanations: first, we focused exclusively on non-pharmacological and non-surgical interventions  
368 for chronic primary musculoskeletal pain, whereas Sherriff et al.<sup>50</sup> included only treatments for  
369 chronic low back pain. Sherriff et al.<sup>50</sup> included a broader range of treatment comparisons, which  
370 included interventions that differed not only in the contextual effects but also in the specific  
371 treatment components (e.g., cognitive functional therapy vs. exercise training + manual therapy).  
372 Including diverse treatment comparisons may introduce bias and makes it challenging to isolate  
373 and estimate the specific effect of enhancing contextual effects alone. Consequently, it is difficult  
374 to draw definitive conclusions regarding the impact of enhancing contextual effects on the  
375 outcomes of interest from the prior review. In contrast to the Sherriff review<sup>50</sup>, we used a  
376 quantitative approach via meta-analysis. By avoiding vote counting and conducting a  
377 comprehensive synthesis of data, we provided a more robust and reliable evaluation of the effects  
378 of enhancing contextual effects in non-pharmacological and non-surgical interventions for chronic  
379 primary musculoskeletal pain.

380 We employed a comprehensive search strategy that included forward and backward citation  
381 tracking, and a search of trial registries, minimising the risk of missing important evidence.  
382 Additionally, we assessed the certainty of the evidence using the GRADE framework, allowing for  
383 a systematic and transparent evaluation of the quality and confidence in the findings.

384 Enhancing contextual effects when treating chronic primary musculoskeletal pain had a generally  
385 small or trivial effect on outcomes. While there may be some minor effects, they may not have  
386 substantial clinical significance in terms of pain intensity, physical functioning, global ratings of  
387 improvement, or self-reported quality of life. Clinicians should consider these findings when  
388 weighing the potential benefits of enhancing contextual effects against other treatment options and  
389 patient preferences—there is likely limited impact of enhancing contextual effects.

390 While previous research has emphasized the importance of patient expectations, communication,  
391 and environmental factors in influencing treatment outcomes, our review suggests that enhancing  
392 these factors alone may not substantially improve outcomes. We underscore the need for a multi-  
393 modal and individualized approach to managing chronic musculoskeletal pain that incorporates a  
394 range of strategies beyond contextual enhancements. We urge clinicians to avoid overemphasizing  
395 the role of enhancing contextual effects for chronic primary musculoskeletal pain. Instead, we  
396 suggest focus on treatment approach that integrates various evidence-based interventions. Patient-  
397 centered care and shared decision-making remain crucial in tailoring treatment plans to individual  
398 needs and preferences.<sup>30</sup> From a healthcare policy perspective, these findings suggest the  
399 importance of allocating resources towards interventions that have demonstrated more robust and  
400 clinically significant effects on pain management and functional improvement in chronic primary  
401 musculoskeletal pain.<sup>3,33</sup>

## 402 **Limitations**

403 Other factors such as patient subgroups, pain duration, contextual enhancement type could affect  
404 the outcomes and moderate the effects of enhancing contextual effects. Therefore, definitive  
405 conclusions about the role of contextual effects in enhancing treatment efficacy for musculoskeletal  
406 pain cannot be drawn from this study alone. We only included randomized clinical trials (RCTs)

407 written in German or English language, although adding non-English trials does not significantly  
408 impact effect size estimates.<sup>43</sup> Risk of bias was rated only for one outcome and the last follow-up  
409 time-point. A limitation of subgroup analyses with such a low number of trials ( $k \leq 4$  per subgroup)  
410 is their very low power to detect an effect.<sup>29</sup> Future research should aim to improve the quality and  
411 rigor of the trials on this topic, by using factorial designs that can isolate and manipulate different  
412 contextual effects, increasing sample size to achieve adequate statistical power, and enhancing  
413 patient expectations through more elaborate interventions similar to open-label placebo trials  
414 .<sup>14,31,54</sup> In addition, it would be interesting to explore whether some individuals are more responsive  
415 to placebo effects or contextual influences than others, and what are the underlying mechanisms  
416 for this variability. This could be related to psychological factors such as personality traits, beliefs,  
417 or emotions, or biological factors such as genetic variations or neurobiological responses. This is  
418 an important area for future research that could have implications for personalized medicine and  
419 how treatment is delivered.

420 The trials included in the analysis showed variations in design, interventions, and outcome  
421 measures, causing heterogeneity, and potentially impacting the comparability of results. The  
422 limited number of trials prevented further exploration of heterogeneity through meta-regression or  
423 subgrouping. Assigning individual trial interventions to specific enhancement categories involves  
424 subjective judgment. The chosen route or execution of enhancing an intervention may not be  
425 adequate. The challenge of determining universally applicable values for thresholds of clinical  
426 relevance in the analysis could be improved by considering lower ranges of equivalence. However,  
427 the lack of smallest-worthwhile-effect (SWE) studies hinders establishing specific lower  
428 thresholds. Further exploration and discussion are needed to refine these thresholds based on  
429 context-specific considerations.

430 **Conclusion**

431 Enhancing contextual effects in non-pharmacological and non-surgical interventions for chronic  
432 primary musculoskeletal pain likely has limited clinical application. Although some individual  
433 trials reported larger effects, the findings were based on small sample sizes and were susceptible  
434 to bias.

Table 1 - Study descriptions

Author Year	Primary Musculoskeletal Condition	Duration Of Complaints (weeks)	Study Design	Population Enrolled (N)	Mean Age (Sd)	Female (N)	Intervention Duration (weeks)	Intervention Label	Enhancement Category	Group Label	Total Number Of Arms	Outcome	Follow-Up (weeks)	Scale Information	Study Funding	Competing Interest
Akbaba 2018	Rotator Cuff-related Shoulder Pain	55	Parallel RCT	33	50.03 (10.22)	22	0.14	Aids & devices	None	CON	3	Pain intensity; Physical functioning	0.07; 0.14	VAS-Rest; VAS-Activity; VAS-night; DASH; ASES	no support	state no conflict of interest
Akbaba 2018	Rotator Cuff-related Shoulder Pain	40	Parallel RCT	33	48.86 (10.3)	17	0.14	Aids & devices	Patient's beliefs and characteristics	INT	3	Pain intensity; Physical functioning	0.07; 0.14	VAS-Rest; VAS-Activity; VAS-night; DASH; ASES	no support	state no conflict of interest
Barth 2021	Low Back Pain	457.4	Parallel RCT	75	39.1 (12)	51	4	Acupuncture	None	CON	2	Pain intensity	4; 26	NRS or NPRS	government	state no conflict of interest
Barth 2021	Low Back Pain	381.3	Parallel RCT	77	40 (13.1)	49	4	Acupuncture	Patient's beliefs and characteristics	INT	2	Pain intensity	4; 26	NRS or NPRS	government	state no conflict of interest



Author Year	Primary Musculoskeletal Condition	Duration Of Complaints (weeks)	Study Design	Population Enrolled (N)	Mean Age (Sd)	Female (N)	Intervention Duration (weeks)	Intervention Label	Enhancement Category	Group Label	Total Number Of Arms	Outcome	Follow-Up (weeks)	Scale Information	Study Funding	Competing Interest
Fuentes 2014	Low Back Pain	197	Parallel RCT	30	30.5 (10.26)	18	0.14	Electrophysical agents	None	CON	4	Pain intensity	0.14	NRS or NPRS	government	NR
Fuentes 2014	Low Back Pain	222.6	Parallel RCT	29	29.7 (11.33)	19	0.14	Electrophysical agents	Patient-practitioner relationship	INT	4	Pain intensity	0.14	NRS or NPRS	government	NR
Kong 2018	Knee Osteoarthritis	NR	Parallel RCT	20	61.2 (7.7)	10	4	Acupuncture	None	CON	3	Pain intensity; Physical functioning; Self-reported quality of life	4	KOOS Pain subscale VAS-Rest	government	one author declares possible COI
Kong 2018	Knee Osteoarthritis	NR	Parallel RCT	24	61.3 (6.9)	9	4	Acupuncture	Patient's beliefs and characteristics	INT	3	Pain intensity; Physical functioning; Self-reported quality of life	4	KOOS Pain subscale VAS-Rest	government	one author declares possible COI
Lonsdale 2017	Low Back Pain	NR	Cluster RCT	122	46.71 (13.48)	64	NR	Physical therapy	None	CON	2	Global rating of improvement; Pain intensity; Physical	24	Perception of Recovery Scale; NRS or NPRS ;	government	one author declares

Author Year	Primary Musculoskeletal Condition	Duration Of Complaints (weeks)	Study Design	Population Enrolled (N)	Mean Age (Sd)	Female (N)	Intervention Duration (weeks)	Intervention Label	Enhancement Category	Group Label	Total Number Of Arms	Outcome	Follow-Up (weeks)	Scale Information	Study Funding	Competing Interest
Lonsdale 2017	Low Back Pain	NR	Cluster RCT	131	44.11 (12.96)	73	NR	Physical therapy	Patient-practitioner relationship	INT	2	functioning; Self-reported quality of life	24	European Quality of Life Questionnaire EurQoL	government	possible COI
Martínez-Cervera 2017	Lateral Epicondylalgia	18	Parallel RCT	12	55.03 (8.09)	7	1	Manual therapies and manipulation	None	CON	2	Pain intensity; Physical functioning	1	VAS ; DASH	NR	state no conflict of interest
Martínez-Cervera 2017	Lateral Epicondylalgia	14.5	Parallel RCT	12	48.08 (11.25)	6	1	Manual therapies and manipulation	Patient's beliefs and characteristics	INT	2	Pain intensity; Physical functioning	1	VAS ; DASH	NR	state no conflict of

Author Year	Primary Musculoskeletal Condition	Duration Of Complaints (weeks)	Study Design	Population Enrolled (N)	Mean Age (Sd)	Female (N)	Intervention Duration (weeks)	Intervention Label	Enhancement Category	Group Label	Total Number Of Arms	Outcome	Follow-Up (weeks)	Scale Information	Study Funding	Competing Interest
Miyamoto 2021	Low Back Pain	345.67	Parallel RCT	74	47.2 (14.8)	38	2	Education	None	CON	3	Global rating of improvement; Pain intensity; Physical functioning	4.34; 26; 52	Global perceived effect	government	interest state no conflict of interest
Miyamoto 2021	Low Back Pain	368.28	Parallel RCT	74	46 (14.7)	46	2	Education	Patient-practitioner relationship	INT	3	Global rating of improvement; Pain intensity; Physical functioning	4.34; 26; 52	Global perceived effect	government	state no conflict of interest
Morrall 2019	Plantar Heel Pain	57.7	Parallel RCT	45	48.27 (9.96)	15	3	Electrophysiological agents	None	CON	3	Pain intensity; Physical functioning	4; 8; 17; 60	VAS - pain with the first weight-bearing step in the morning; VAS - pain during	NR	NR

Author Year	Primary Musculoskeletal Condition	Duration Of Complaints (weeks)	Study Design	Population Enrolled (N)	Mean Age (Sd)	Female (N)	Intervention Duration (weeks)	Intervention Label	Enhancement Category	Group Label	Total Number Of Arms	Outcome	Follow-Up (weeks)	Scale Information	Study Funding	Competing Interest
Morrall 2019	Plantar Heel Pain	65	Parallel RCT	45	52.51 (12.28)	27	3	Electrophysiological agents	Treatment characteristics	INT	3	Pain intensity; Physical functioning	4; 8; 17; 60	the day; FFI VAS - pain with the first weight-bearing step in the morning; VAS - pain during the day; FFI	NR	NR
Sandal 2019	Hip and Knee Osteoarthritis	765	Parallel RCT	40	57.6 (9.8)	25	8	Exercise	None	CON	3	Global rating of improvement; Pain intensity; Physical functioning; Self-reported quality of life	8	Global Perceived Effect	government	state no conflict of interest
Sandal 2019	Hip and Knee Osteoarthritis	730	Parallel RCT	42	59.6 (10.9)	25	8	Exercise	Therapeutic setting/environment	INT	3	Global rating of improvement; Pain	8	Global Perceived Effect	government	state no conflict of

Author Year	Primary Musculoskeletal Condition	Duration Of Complaints (weeks)	Study Design	Population Enrolled (N)	Mean Age (Sd)	Female (N)	Intervention Duration (weeks)	Intervention Label	Enhancement Category	Group Label	Total Number Of Arms	Outcome	Follow-Up (weeks)	Scale Information	Study Funding	Competing Interest
												intensity; Physical functioning; Self-reported quality of life				interest
Vong 2011	Low Back Pain	221	Parallel RCT	38	45.1 (10.7)	26	8	Physical therapy	None	CON	2	Pain intensity; Physical functioning	8; 12	VAS	NR	state no conflict of interest
Vong 2011	Low Back Pain	180	Parallel RCT	38	44.6 (11.2)	22	8	Physical therapy	Patient-practitioner relationship	INT	2	Pain intensity; Physical functioning	8; 12	VAS	NR	state no conflict of interest

436 NR: Not reported.

**Table 2: Detailed description of enhancement categories**

Author Year	Primary Musculoskeletal Condition	Intervention Label	Enhancement Category	Enhancement Description
Akbaba 2018	Rotator Cuff-related Shoulder Pain	Aids & devices—Orthotics, tapes, braces, collars, insoles and other support devices	Patient's beliefs and characteristics (e.g., medical history, illness and treatment beliefs, expectations, or prior experiences)	Group 3: Received standardized therapeutic kinesiotape application. Group 3 received verbal input that there is evidence of excellent effectiveness (positive).
Akbaba 2018	Rotator Cuff-related Shoulder Pain	Aids & devices—Orthotics, tapes, braces, collars, insoles and other support devices	None	Group 1: Received standardized therapeutic kinesiotape application. Group 1 received verbal input that there is no evidence that kinesiotaping is effective (nocebo). Group 2: Received standardized therapeutic kinesiotape application. Group 2 received neutral verbal input that there is limited evidence of effectiveness (neutral).
Barth 2021	Low Back Pain	Acupuncture	Patient's beliefs and characteristics (e.g., medical history, illness and treatment beliefs, expectations, or prior experiences)	Received standardized intervention consisting of 2 oral briefing sessions and written materials delivered by a single physician, followed by 2 booster emails after acupuncture sessions 3 and 6. Received minimal acupuncture for free (8 sessions, 2 times per week for 45 minutes) delivered by 3 specially trained treatment practitioners. Could use nonsteroidal anti-inflammatory drugs but were asked to document this in a medication diary. High expectation group, emphasis was placed on the clinically relevant difference between acupuncture and usual care (responder rates, 48%vs 27%) based on the findings of an earlier study.
Barth 2021	Low Back Pain	Acupuncture	None	Received standardized intervention consisting of 2 oral briefing sessions and written materials delivered by a single physician, followed by 2 booster emails after acupuncture sessions 3 and 6. Received minimal acupuncture for free (8 sessions, 2 times per week for 45 minutes)

Author Year	Primary Musculoskeletal Condition	Intervention Label	Enhancement Category	Enhancement Description
Fuentes 2014	Low Back Pain	Electrophysical agents	Patient-practitioner relationship (e.g., therapeutic alliance, trust, verbal or non-verbal communication, reassurance)	<p>delivered by 3 specially trained treatment practitioners. Could use nonsteroidal anti-inflammatory drugs but were asked to document this in a medication diary. Low expectation group, emphasis was placed on the small difference between acupuncture and sham acupuncture (responder rates, 48%vs 44%) based on the findings of an earlier study.</p> <p>Group 1: Active IFC for 30 minutes with enhanced therapeutic interaction [During the first 10 minutes, each participant was questioned about his or her symptoms and lifestyle and about the cause of his or her condition. The therapeutic interaction was enhanced through verbal behaviors, including active listening (ie, repeating the patient’s words, asking for clarifications), tone of voice, nonverbal behaviors (ie, eye contact, physical touch), and empathy (such as saying, “I can understand how difficult LBP must be for you.”). This intervention model aimed to create an optimal patient/clinician relationship. The therapist then stayed in the room during the entire treatment and during the measurement of outcomes. During this time, verbal interaction between the therapist and participant was encouraged. Finally, at the end of the session, few words of encouragement were given.]</p>
Fuentes 2014	Low Back Pain	Electrophysical agents	None	<p>Group 2: Active IFC for 30 minutes [The limited interaction included about 5 minutes during which the therapist introduced herself and explained the purpose of the treatment. In addition, participants were told that this was a “scientific study” in which the therapist had been instructed not to converse with participants.],</p>

Author Year	Primary Musculoskeletal Condition	Intervention Label	Enhancement Category	Enhancement Description
Kong 2018	Knee Osteoarthritis	Acupuncture	Patient's beliefs and characteristics (e.g., medical history, illness and treatment beliefs, expectations, or prior experiences)	<p>Group 3: Sham IFC with enhanced therapeutic interaction, Group 4: Sham IFC with limited therapeutic interaction</p> <p>Intervention Group (boosted acupuncture): 4 weeks acupuncture treatment (2 times/week for first 2 weeks, then 1 time/week for last 2 weeks) 13 study visits including baseline training, clinical assessment, fMRI scan sessions, acupuncture treatments, and clinical assessments (midpoint and final) Expectancy manipulation during fMRI scan sessions to enhance positive expectation of pain reduction with acupuncture treatment</p>
Kong 2018	Knee Osteoarthritis	Acupuncture	None	<p>Control Group 1 : (Standard Acupuncture Group) 4 weeks acupuncture treatment (2 times/week for first 2 weeks, then 1 time/week for last 2 weeks), 13 study visits including baseline training, clinical assessment, fMRI scan sessions, acupuncture treatments, and clinical assessments (midpoint and final), No expectancy manipulation, Control Group 2 (No treatment): 5 visits including baseline training, clinical assessment, fMRI scan sessions, midpoint assessment, and final assessment, No treatment</p>
Lonsdale 2017	Low Back Pain	Physical therapy (otherwise not falling into specific treatment combination)	Patient-practitioner relationship (e.g., therapeutic alliance, trust, verbal or non-verbal communication, reassurance)	Group 1: one-hour refresher workshop on evidence-based physiotherapy care for chronic low back pain for physiotherapist + eight hours of communication skills training
Lonsdale 2017	Low Back Pain	Physical therapy (otherwise not falling into specific treatment combination)	None	Group 2: care was delivered by a physiotherapist who had completed a 1-hour workshop on evidence-based chronic low back pain management.



Author Year	Primary Musculoskeletal Condition	Intervention Label	Enhancement Category	Enhancement Description
Martínez-Cervera 2017	Lateral Epicondylalgia	Manual therapies and manipulation	Patient's beliefs and characteristics (e.g., medical history, illness and treatment beliefs, expectations, or prior experiences)	Group 1: Mobilization with movement + "The technique that you will receive is very effective for the treatment of lateral epicondylalgia, so we expect that it will reduce your perception of pain". (positive)
Martínez-Cervera 2017	Lateral Epicondylalgia	Manual therapies and manipulation	None	Group 2: Mobilization with movement + "The technique that you will receive is used to treat lateral epicondylalgia, but its effect in pain perception is unknown". (neutral)#
Miyamoto 2021	Low Back Pain	Education	Patient-practitioner relationship (e.g., therapeutic alliance, trust, verbal or non-verbal communication, reassurance)	Intervention Group: The education-plus-TA group received two 60-minute individual treatment sessions with structured sessions aimed at increasing TA and empathy, along with education intervention sessions related to return to daily activities, advice on coping with pain, and a clear explanation of signs and symptoms.
Miyamoto 2021	Low Back Pain	Education	None	Control Group 1 (Education-Only Group): Participants received the same education intervention sessions related to return to daily activities, advice on coping with pain, and a clear explanation of signs and symptoms, but without any emphasis on enhancing the quality of the patient-therapist relationship. Control Group 2 (No-Education Group): Participants received no intervention and were advised not to seek treatment in the first month after randomization.
Morral 2019	Plantar Heel Pain	Electrophysical agents	Treatment characteristics (e.g., continuity of care, labelling, visual cues, sham/dummy treatment, variations in touch or stimulus conditions)	Group 2: standard radial extracorporeal shock wave device modified to give a more sophisticated appearance

Author Year	Primary Musculoskeletal Condition	Intervention Label	Enhancement Category	Enhancement Description
Morral 2019	Plantar Heel Pain	Electrophysical agents	None	Group 1: standard radial extracorporeal shock wave device, Group 3: standard radial extracorporeal shock wave device modified to give a more austere and unattractive, low-tech appearance.
Sandal 2019	Other	Exercise	Therapeutic setting/environment (e.g., setting, layout, décor, interior design)	Group 1: NEMEX (Exercise program) + Physically enhanced environment [The exercise environment is located in a newly built facility on the second floor and has a vista over a sport and recreational park. The room is a designated exercise room. It appears clean and new, with rubberised floors, smooth concrete walls. Decoration includes pictures of landscapes. It is equipped with state of the art exercise equipment.]
Sandal 2019	Other	Exercise	None	Group 2: NEMEX (Exercise Program) + Standard environment [The exercise environment is marked by years of use and resembles many existing exercise facilities at hospitals and rehabilitation clinics. It is located in the basement of an older campus building and has no windows. Access through a series of staircases and dark hallways. The room appears used with polished wooden floors, wall bars, bare, unadorned concrete walls.] Group 3: Waitlist
Vong 2011	Low Back Pain	Physical therapy (otherwise not falling into specific treatment combination)	Patient-practitioner relationship (e.g., therapeutic alliance, trust, verbal or non-verbal communication, reassurance)	Group 1: Conventional PT [Ten 30-minute sessions in 8 weeks, Interferential Therapy, Exercise Program Home Exercise Program] + Treatment is with PT's that were specifically training in Motivational Enhancement Therapy (MET) [Motivational-Enhanced Therapy (MET) is a therapeutic approach that integrates motivational interviewing (MI) techniques and psychosocial

Author Year	Primary Musculoskeletal Condition	Intervention Label	Enhancement Category	Enhancement Description
				components to enhance patients' motivation to engage in treatment and make appropriate behavioral changes. Some of the key psychosocial factors relevant to the motivational approach include proxy efficacy, treatment expectancy, and working alliance.]
Vong 2011	Low Back Pain	Physical therapy (otherwise not falling into specific treatment combination)	None	Group 2: Conventional PT [Ten 30-minute sessions in 8 weeks, Interferential Therapy, Exercise Program Home Exercise Program]

**Table 3 - Results with GRADE ratings**

Outcome	Analysis Timepoint	Number Of Trials	Trials Included In Analysis	Number Of Participants (Dropouts)	Estimate (MD/ SMD)	Prediction Interval (PI)	Tau	I <sup>2</sup>	Final Grade Rating
Pain Intensity	immediate	2	Akbaba 2018; Fuentes 2014	125 (4)	MD: -7.99, 95%CI: [-77.46; 61.47]		7.02	0.82, 95%- CI: [0.23; 0.96]	Very Low,f,g
Pain Intensity	short-term	7	Barth 2021; Kong 2018; Martínez-Cervera 2017; Miyamoto 2021; Morral 2019; Sandal 2019; Vong 2011	719 (67)	MD: -1.77, 95%CI: [-8.71; 5.16]	95%-PI: [- 19.51; 15.96]	6.29	0.69, 95%- CI: [0.32; 0.86]	Low,h
Pain Intensity	intermediate-term	5	Barth 2021; Lonsdale 2017; Miyamoto 2021; Morral 2019; Vong 2011	238 (22)	MD: -0.81, 95%CI: [-6; 4.38]	95%-PI: [- 6.76; 5.14]	0.00	0.07, 95%- CI: [0; 0.81]	High
Pain Intensity	long-term	2	Miyamoto 2021; Morral 2019	616 (21)	MD: -0.49, 95%CI: [-6.37; 5.4]		0.00		High
Physical Function	immediate	1	Akbaba 2018	66 (7)	MD: 1.2, 95%-CI: [0.65; 1.75]				High
Physical Function	short-term	6	Kong 2018; Martínez-Cervera 2017; Miyamoto 2021; Morral 2019; Sandal 2019; Vong 2011	567 (67)	MD: -0.27, 95%- CI: [-1.02; 0.49]	95%-PI: [- 2.04; 1.51]	0.57	0.68, 95%- CI: [0.25; 0.87]	Low,h
Physical Function	intermediate-term	4	Lonsdale 2017; Miyamoto 2021; Morral 2019; Vong 2011	238 (22)	MD: -0.1, 95%- CI: [-1.08; 0.88]		0.47	0.57, 95%- CI: [0; 0.86]	Moderate,e
Physical Function	long-term	2	Miyamoto 2021; Morral 2019	464 (21)	MD: -0.9, 95%- CI: [-8.32; 6.55]		0.73	0.78, 95%- CI: [0.02; 0.95]	Low,f
Global Rating of Change	short-term	2	Miyamoto 2021; Sandal 2019	148 (19)	SMD: 0.18, 95%- CI: [-2.16; 2.52]		0.16		Low,f

Outcome	Analysis Timepoint	Number Of Trials	Trials Included In Analysis	Number Of Participants (Dropouts)	Estimate (MD/ SMD)	Prediction Interval (PI)	Tau	I <sup>2</sup>	Final Grade Rating
Global Rating of Change	intermediate-term	2	Lonsdale 2017; Miyamoto 2021	401 (64)	SMD: -0.13, 95%-CI: [-0.93; 0.67]		0.00		Low,f
Global Rating of Change	long-term	1	Miyamoto 2021	230 (12)	SMD: -0.39, 95%-CI: [-0.77; -0.01]				High
Quality of Life	short-term	2	Kong 2018; Sandal 2019	253 (46)	MD: 0.31, 95%-CI: [-37.64; 38.15]		3.67	0.74, 95%-CI: [0; 0.94]	Very Low a,f
Quality of Life	intermediate-term	1	Lonsdale 2017	126 (7)	MD: 1.43, 95%-CI: [-1.94; 4.79]				High

440 a or b : Downgraded by one or two levels due to risk of bias; c or d: Downgraded by one or two levels due to indirectness; e or f: Downgraded by one or  
441 two levels due to imprecision; g or h: Downgraded by one or two levels due to inconsistency; i or j Downgraded by one or two levels due to publication  
442 bias.




Figure 1: PRISMA Flow Chart




Figure 2: Forest Plot - Pain Intensity (0-100 scale), summary estimate for the time-point "immediate" not shown because of very wide CI, ([MD] : -7.99, 95%-CI: [-77.46; 61.47])




Figure 3: Forest Plot - Physical Function (0-10 scale), summary estimate for the time-point "long-term" not shown because of very wide CI, (MD: , 95%-CI: [; ])






Figure 4: Forest Plot - Global Rating of Change (SMD scale)




Figure 5: Forest Plot - Quality of Life (0-100 scale)

449 **References**

- 450 1. Analay Akbaba Y, Kaya Mutlu E, Altun S, Celik D. Does the patients' expectations on  
451 kinesiotape affect the outcomes of patients with a rotator cuff tear? A randomized controlled  
452 clinical trial. *Clinical Rehabilitation*. Published online July 26, 2018:026921551877964.  
453 doi:[10.1177/0269215518779645](https://doi.org/10.1177/0269215518779645)
- 454 2. Ardern CL, Büttner F, Andrade R, et al. Implementing the 27 PRISMA 2020 Statement  
455 items for systematic reviews in the sport and exercise medicine, musculoskeletal rehabilitation  
456 and sports science fields: the PERSiST (implementing Prisma in Exercise, Rehabilitation, Sport  
457 medicine and SporTs science) guidance. *British Journal of Sports Medicine*. Published online  
458 October 8, 2021. doi:[10.1136/bjsports-2021-103987](https://doi.org/10.1136/bjsports-2021-103987)
- 459 3. Babatunde OO, Jordan JL, Windt DAV der, Hill JC, Foster NE, Protheroe J. Effective  
460 treatment options for musculoskeletal pain in primary care: A systematic overview of current  
461 evidence. *PLOS ONE*. 2017;12(6):e0178621. doi:[10.1371/journal.pone.0178621](https://doi.org/10.1371/journal.pone.0178621)
- 462 4. Badarin K, Hemmingsson T, Hillert L, Kjellberg K. The impact of musculoskeletal pain  
463 and strenuous work on self-reported physical work ability: a cohort study of Swedish men and  
464 women. *International Archives of Occupational and Environmental Health*. 2022;95(5):939-952.  
465 doi:[10.1007/s00420-021-01816-6](https://doi.org/10.1007/s00420-021-01816-6)
- 466 5. Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical  
467 tutorial. *Evidence-based mental health*. 2019;22(4):153160.
- 468 6. Balk EM, Earley A, Patel K, Trikalinos TA, Dahabreh IJ. Empirical Assessment of  
469 Within-Arm Correlation Imputation in Trials of Continuous Outcome. Published online 2012.  
470 <https://www.ncbi.nlm.nih.gov/books/NBK115797>

- 471 7. Barth J, Muff S, Kern A, et al. Effect of Briefing on Acupuncture Treatment Outcome  
472 Expectations, Pain, and Adverse Side Effects Among Patients With Chronic Low Back Pain: A  
473 Randomized Clinical Trial. *JAMA Network Open*. 2021;4(9):e2121418.  
474 doi:[10.1001/jamanetworkopen.2021.21418](https://doi.org/10.1001/jamanetworkopen.2021.21418)
- 475 8. Benedetti F. Placebo and the new physiology of the doctor-patient relationship.  
476 *Physiological Reviews*. 2013;93(3):1207-1246. doi:[10.1152/physrev.00043.2012](https://doi.org/10.1152/physrev.00043.2012)
- 477 9. Benedetti F. Placebo effects: From the neurobiological paradigm to translational  
478 implications. *Neuron*. 2014;84(3):623-637. doi:[10.1016/j.neuron.2014.10.023](https://doi.org/10.1016/j.neuron.2014.10.023)
- 479 10. Benedetti F, Carlino E, Pollo A. How Placebos Change the Patient's Brain.  
480 *Neuropsychopharmacology*. 2011;36(1):339-354. doi:[10.1038/npp.2010.81](https://doi.org/10.1038/npp.2010.81)
- 481 11. Borenstein M. *Common Mistakes in Meta-Analysis: And How to Avoid Them*.
- 482 12. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to meta-analysis.  
483 Published online 2009.
- 484 13. Carrer HCN, Lima TC de, George SZ, et al. Investigating the hypoalgesic effects of spinal  
485 manipulative therapy using hidden pain conditioning and positive expectation in patients with  
486 chronic low back pain: protocol for a randomised controlled trial. *BMJ Open*.  
487 2023;13(4):e066199. doi:[10.1136/bmjopen-2022-066199](https://doi.org/10.1136/bmjopen-2022-066199)
- 488 14. Carvalho C, Caetano JM, Cunha L, Rebouta P, Kaptchuk TJ, Kirsch I. Open-label placebo  
489 treatment in chronic low back pain: a randomized controlled trial. *Pain*. 2016;157(12):2766-  
490 2772. doi:[10.1097/j.pain.0000000000000700](https://doi.org/10.1097/j.pain.0000000000000700)

- 491 15. Cohen J. *Statistical Power Analysis for the Behavioral Sciences*. 2nd Edn. Á/L. Erbaum  
492 Press; 1988.
- 493 16. Cuyul-Vásquez I, Fuentes C J. Effects of therapeutic alliance on clinical outcomes in  
494 patients with symptomatic knee osteoarthritis undergoing an exercise program: A randomized  
495 clinical trial protocol. *Medwave*. 2021;21(3):e8160. doi:[10.5867/medwave.2021.03.8159](https://doi.org/10.5867/medwave.2021.03.8159)
- 496 17. Daly C, Welton NJ, Dias S, Anwer S, Ades A. Guideline Methodology Document 2. :49.
- 497 18. Di Blasi Z, Harkness E, Ernst E, Georgiou A, Kleijnen J. Influence of context effects on  
498 health outcomes: A systematic review. *The Lancet*. 2001;357(9258):757762.
- 499 19. Dias S, Ades AE, Welton NJ, Jansen JP, Sutton AJ. *Network Meta-Analysis for Decision-*  
500 *Making*. John Wiley & Sons; 2018.
- 501 20. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical  
502 trials: IMMPACT recommendations. *Pain*. 2005;113(1):9-19. doi:[10.1016/j.pain.2004.09.012](https://doi.org/10.1016/j.pain.2004.09.012)
- 503 21. Flemyng E, Moore TH, Boutron I, et al. Using Risk of Bias 2 to assess results from  
504 randomised controlled trials: guidance from Cochrane. *BMJ Evidence-Based Medicine*.  
505 2023;28(4):260-266. doi:[10.1136/bmjebm-2022-112102](https://doi.org/10.1136/bmjebm-2022-112102)
- 506 22. Fuentes J, Armijo-Olivo S, Funabashi M, et al. Enhanced Therapeutic Alliance Modulates  
507 Pain Intensity and Muscle Pain Sensitivity in Patients With Chronic Low Back Pain: An  
508 Experimental Controlled Study. *Physical Therapy*. 2014;94(4):477-489.  
509 doi:[10.2522/ptj.20130118](https://doi.org/10.2522/ptj.20130118)
- 510 23. Garnaes KK, Mørkved S, Salvesen Ø, et al. What factors are associated with health-  
511 related quality of life among patients with chronic musculoskeletal pain? A cross-sectional study

- 512 in primary health care. *BMC Musculoskeletal Disorders*. 2021;22(1):102. doi:10.1186/s12891-  
513 020-03914-x
- 514 24. Garnæs KK, Mørkved S, Tønne T, Furan L, Vasseljen O, Johannessen HH. Mental health  
515 among patients with chronic musculoskeletal pain and its relation to number of pain sites and  
516 pain intensity, a cross-sectional study among primary health care patients. *BMC Musculoskeletal*  
517 *Disorders*. 2022;23(1):1115. doi:10.1186/s12891-022-06051-9
- 518 25. *Get Data Graph Digitizer*. <https://getdata-graph-digitizer.software.informer.com/>
- 519 26. Gøtzsche PC. Why we need a broad perspective on meta-analysis. *BMJ : British Medical*  
520 *Journal*. 2000;321(7261):585-586. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1118486/>
- 521 27. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 8. Rating the quality of  
522 evidence—indirectness. *Journal of Clinical Epidemiology*. 2011;64(12):1303-1310.  
523 doi:10.1016/j.jclinepi.2011.04.014
- 524 28. Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: An R package  
525 and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for  
526 optimised digital transparency and Open Synthesis. *Campbell Systematic Reviews*.  
527 2022;18(2):e1230. doi:10.1002/cl2.1230
- 528 29. Higgins JPT, Thomas J, Chandler J. *Cochrane Handbook for Systematic Reviews of*  
529 *Interventions*. John Wiley & Sons; 2019.
- 530 30. Hoffmann TC, Lewis J, Maher CG. Shared decision making should be an integral part of  
531 physiotherapy practice. *Physiotherapy*. 2020;107:43-49. doi:10.1016/j.physio.2019.08.012

- 532 31. Kleine-Borgmann J, Dietz TN, Schmidt K, Bingel U. No long-term effects after a 3-week  
533 open-label placebo treatment for chronic low back pain: a 3-year follow-up of a randomized  
534 controlled trial. *Pain*. 2023;164(3):645-652. doi:[10.1097/j.pain.0000000000002752](https://doi.org/10.1097/j.pain.0000000000002752)
- 535 32. Kong J, Wang Z, Leiser J, et al. Enhancing treatment of osteoarthritis knee pain by  
536 boosting expectancy: A functional neuroimaging study. *NeuroImage: Clinical*. 2018;18:325-334.  
537 doi:[10.1016/j.nicl.2018.01.021](https://doi.org/10.1016/j.nicl.2018.01.021)
- 538 33. Lin I, Wiles L, Waller R, et al. What does best practice care for musculoskeletal pain look  
539 like? Eleven consistent recommendations from high-quality clinical practice guidelines:  
540 systematic review. *Br J Sports Med*. 2020;54:7986.
- 541 34. Lonsdale C, Hall AM, Murray A, et al. Communication Skills Training for Practitioners  
542 to Increase Patient Adherence to Home-Based Rehabilitation for Chronic Low Back Pain: Results  
543 of a Cluster Randomized Controlled Trial. *Archives of Physical Medicine and Rehabilitation*.  
544 2017;98(9):1732-1743.e7. doi:[10.1016/j.apmr.2017.02.025](https://doi.org/10.1016/j.apmr.2017.02.025)
- 545 35. Martínez-Cervera FV, Olteanu TE, Gil-Martínez A, Díaz-Pulido B, Ferrer-Peña R.  
546 Influence of expectations plus mobilization with movement in patient with lateral epicondylalgia:  
547 a pilot randomized controlled trial. *Journal of Exercise Rehabilitation*. 2017;13(1):101-109.  
548 doi:[10.12965/jer.1732848.424](https://doi.org/10.12965/jer.1732848.424)
- 549 36. Miyamoto GC, Fagundes FRC, de Melo do Espírito Santo C, et al. Education With  
550 Therapeutic Alliance Did Not Improve Symptoms in Patients With Chronic Low Back Pain and  
551 Low Risk of Poor Prognosis Compared to Education Without Therapeutic Alliance: A  
552 Randomized Controlled Trial. *Journal of Orthopaedic & Sports Physical Therapy*.  
553 2021;51(8):392-400. doi:[10.2519/jospt.2021.9636](https://doi.org/10.2519/jospt.2021.9636)

- 554 37. Morral A, Urrútia G, Gich I, Ruiz R, Bonfill X. Radial extracorporeal shock wave device  
555 appearance does not influence clinical outcomes: A randomized controlled trial. *Journal of*  
556 *Rehabilitation Medicine*. 2019;51(3):201-208. doi:[10.2340/16501977-2516](https://doi.org/10.2340/16501977-2516)
- 557 38. NCT03673319. The patient expectation in dry needling and analgesia. Published online  
558 2018. <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01663304/full>
- 559 39. NCT03928054. Immediate effects of alliance therapy in modulation of pain and disability  
560 in subjects with knee osteoarthritis. *Trial Registration NIH*.  
561 <https://ClinicalTrials.gov/show/NCT03928054>.
- 562 40. NCT04636879. Dry needling and patients treatment expectations. Published online 2020.  
563 <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02205757/full>
- 564 41. Nikolakopoulou A, Higgins JPT, Papakonstantinou T, et al. CINeMA: An approach for  
565 assessing confidence in the results of a network meta-analysis. *PLOS Medicine*.  
566 2020;17(4):e1003082. doi:[10.1371/journal.pmed.1003082](https://doi.org/10.1371/journal.pmed.1003082)
- 567 42. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality  
568 of life: the remarkable universality of half a standard deviation. *Medical Care*. 2003;41(5):582-  
569 592. doi:[10.1097/01.MLR.0000062554.74615.4C](https://doi.org/10.1097/01.MLR.0000062554.74615.4C)
- 570 43. Nussbaumer-Streit B, Klerings I, Dobrescu AI, et al. Excluding non-english publications  
571 from evidence-syntheses did not change conclusions: A meta-epidemiological study. *Journal of*  
572 *Clinical Epidemiology*. 2020;118:42-54. doi:[10.1016/j.jclinepi.2019.10.011](https://doi.org/10.1016/j.jclinepi.2019.10.011)
- 573 44. Overview | Low back pain and sciatica in over 16s: assessment and management |  
574 Guidance | NICE. Published online November 30, 2016. <https://www.nice.org.uk/guidance/ng59>



- 575 45. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated  
576 guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. doi:[10.1136/bmj.n71](https://doi.org/10.1136/bmj.n71)
- 577 46. Perrot S, Cohen M, Barke A, et al. The IASP classification of chronic pain for ICD-11:  
578 Chronic secondary musculoskeletal pain. *PAIN*. 2019;160(1):77.  
579 doi:[10.1097/j.pain.0000000000001389](https://doi.org/10.1097/j.pain.0000000000001389)
- 580 47. Safiri S, Kolahi AA, Cross M, et al. Prevalence, Deaths, and Disability-Adjusted Life  
581 Years Due to Musculoskeletal Disorders for 195 Countries and Territories 1990-2017. *Arthritis &*  
582 *Rheumatology*. 2021;73(4):702-714. doi:[10.1002/art.41571](https://doi.org/10.1002/art.41571)
- 583 48. Sandal LF, Thorlund JB, Moore AJ, Ulrich RS, Dieppe PA, Roos EM. Room for  
584 improvement: a randomised controlled trial with nested qualitative interviews on space, place and  
585 treatment delivery. *British Journal of Sports Medicine*. 2019;53(6):359-367.  
586 doi:[10.1136/bjsports-2016-097448](https://doi.org/10.1136/bjsports-2016-097448)
- 587 49. Sebbag E, Felten R, Sagez F, Sibilila J, Devilliers H, Arnaud L. The world-wide burden of  
588 musculoskeletal diseases: a systematic analysis of the World Health Organization Burden of  
589 Diseases Database. *Annals of the Rheumatic Diseases*. 2019;78(6):844-848.  
590 doi:[10.1136/annrheumdis-2019-215142](https://doi.org/10.1136/annrheumdis-2019-215142)
- 591 50. Sherriff B, Clark C, Killingback C, Newell D. Impact of contextual factors on patient  
592 outcomes following conservative low back pain treatment: systematic review. *Chiropractic &*  
593 *Manual Therapies*. 2022;30(1):20. doi:[10.1186/s12998-022-00430-8](https://doi.org/10.1186/s12998-022-00430-8)
- 594 51. Stanley TD, Doucouliagos H, Ioannidis JP. Beyond random effects: When small-study  
595 findings are more heterogeneous. *Advances in Methods and Practices in Psychological Science*.  
596 2022;5(4):25152459221120427.

- 597 52. Sterne JAC, Savović J, Page MJ. RoB 2: a revised tool for assessing risk of bias in  
598 randomised trials. *BMJ*. 2019;366. doi:[10.1136/bmj.14898](https://doi.org/10.1136/bmj.14898)
- 599 53. Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and  
600 interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ*.  
601 2011;343:d4002. doi:[10.1136/bmj.d4002](https://doi.org/10.1136/bmj.d4002)
- 602 54. Strijkers RHW, Schreijenberg M, Gerger H, Koes BW, Chiarotto A. Effectiveness of  
603 placebo interventions for patients with nonspecific low back pain: a systematic review and meta-  
604 analysis. *Pain*. 2021;Publish Ahead of Print. doi:[10.1097/j.pain.0000000000002272](https://doi.org/10.1097/j.pain.0000000000002272)
- 605 55. Testa M, Rossetini G. Enhance placebo, avoid nocebo: How contextual factors affect  
606 physiotherapy outcomes. *Manual Therapy*. 2016;24:65-74. doi:[10.1016/j.math.2016.04.006](https://doi.org/10.1016/j.math.2016.04.006)
- 607 56. Treede RD, Rief W, Barke A, et al. A classification of chronic pain for ICD-11. *Pain*.  
608 2015;156(6):1003-1007. doi:[10.1097/j.pain.0000000000000160](https://doi.org/10.1097/j.pain.0000000000000160)
- 609 57. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. *Journal of*  
610 *Statistical Software*. 2010;36(1):148. doi:[10.18637/jss.v036.i03](https://doi.org/10.18637/jss.v036.i03)
- 611 58. Viechtbauer W, Cheung MW-L. Outlier and influence diagnostics for meta-analysis.  
612 *Research Synthesis Methods*. 2010;1(2):112125. doi:[10.1002/jrsm.11](https://doi.org/10.1002/jrsm.11)
- 613 59. Vong SK, Cheing GL, Chan F, So EM, Chan CC. Motivational Enhancement Therapy in  
614 Addition to Physical Therapy Improves Motivational Factors and Treatment Outcomes in People  
615 With Low Back Pain: A Randomized Controlled Trial. *Archives of Physical Medicine and*  
616 *Rehabilitation*. 2011;92(2):176-183. doi:[10.1016/j.apmr.2010.10.016](https://doi.org/10.1016/j.apmr.2010.10.016)

617 60. White IR, Higgins JPT, Wood AM. Allowing for uncertainty due to missing data in meta-  
618 analysisPart 1: Two-stage methods. *Statistics in Medicine*. 2008;27(5):711-727.  
619 doi:[10.1002/sim.3008](https://doi.org/10.1002/sim.3008)